Bind
Therapeutics Inc. (Nasdaq: BIND) reported upbeat interim data for a Phase 2
trial of BIND-014 in metastatic castration resistant prostate cancer and
expects its collaboration partners to file an IND with the Food and
Drug Administration for Accurin by mid-2015 sending the stock price soaring $3.16 to $8.31.
Bind Therapeutics reports positive interim results
January 08, 2015 at 13:21 PM EST
